Pfizer Launches Macugen In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer launched Macugen (pegaptanib sodium injection) in Japan Oct. 14. The first aptamer drug in Japan, Macugen is an anti-vascular endothelial growth factor therapy to help reduce the risk of vision loss in neovascular age-related macular degeneration. Priced at ¥123,457 per set, the 0.3 milligram injection kit will be marketed by medical representatives who are specialized in ophthalmologic drugs. (Click here for more - Japanese language